Treprostinil Use in Interstitial Lung Disease to Increase FVC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new pharmaceutical treatments for interstitial lung disease (ILD), particularly idiopathic pulmonary fibrosis (IPF), as the current FDA-approved drugs nintedanib and pirfenidone have limited effectiveness and the average survival rate for ILD patients is between 3 to 5 years.
Innovation Solution
Administering treprostinil, a prodrug, or its pharmaceutically acceptable salt, to patients with ILD or pulmonary hypertension associated with ILD to improve pulmonary function, reduce pulmonary function decline, and increase forced vital capacity (FVC).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved drugs (nintedanib and pirfenidone) are used for treating ILD, then treatment is available, but effectiveness is limited and survival rate remains low (3-5 years)
Solution Approach 1:
The patent changes the pharmacological parameter by introducing a different drug class (prostacyclin analogs) with novel mechanisms of action compared to existing antifibrotics. This parameter change in treatment approach aims to improve both effectiveness and survival outcomes in ILD patients who have limited response to current therapies
2Reliability
If new pharmaceutical treatments are developed for ILD, then treatment effectiveness may improve, but the complexity of drug development and clinical validation increases
Solution Approach 1:
The patent positions treprostinil as a multi-functional treatment that addresses multiple aspects of ILD pathology including pulmonary hypertension, fibrosis progression, and exercise capacity. This universal approach may simplify development by targeting multiple disease mechanisms with a single agent, potentially reducing overall development complexity despite the novel mechanism
3Manufacturing precision
If treprostinil is administered to increase FVC, then pulmonary function improves significantly (20-100% increase), but the mechanism of action differs from conventional antifibrotic drugs
Solution Approach 1:
The patent introduces treprostinil as an intermediary substance that mediates its effects through the prostacyclin pathway, which is distinct from the mechanisms of conventional antifibrotics. This intermediary mechanism activates multiple downstream effects including pulmonary vasodilation, anti-proliferative effects, and anti-inflammatory actions, achieving significant FVC improvement through this novel mediatory pathway
Data Source
AI summary
Methods of treating of interstitial lung disease, reducing pulmonary function decline in a subject with interstitial lung disease (ILD), and increasing forced vital capacity (FVC) in a subject suffering from ILD are provided, wherein the methods include administration of treprostinil.